Therapy Areas: Inflammatory Diseases
Shilpa Medicare secures approval for NAFLD therapy NorUDCA in India
14 August 2025 - India-based global pharmaceutical company Shilpa Medicare Limited (BSE:530661, NSE:SHILPAMED) announced on Thursday that it has obtained the world's first regulatory approval for...
Remegen's Telitacicept meets Sjogren's syndrome Phase III trial's primary endpoint
14 August 2025 - Remegen (688331.SH/09995.HK), a China-based pharmaceutical company, announced on Wednesday that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacice...
PainReform acquires majority stake in LayerBio to advance dropless cataract surgery therapy
13 August 2025 - PainReform Ltd (Nasdaq:PRFX), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, said on Wednesday that it has acquired a majo...
Seragon launches Enlivien sleep and longevity optimiser
13 August 2025 - California-based pharmaceutical company Seragon Biosciences Inc announced on Tuesday the launch of Enlivien, a sleep and longevity optimiser.The company says that Enlivien integrates ...
Insmed's BRINSUPRI (brensocatib) non-cystic fibrosis bronchiectasis treatment approved by US FDA
13 August 2025 - Insmed Incorporated (Nasdaq: INSM), a US-based global biopharmaceutical company, announced on Tuesday that the US Food and Drug Administration (FDA) has approved first-in-class BRINSU...
Fosun Pharma agrees XH-S004 overseas licensing deal
12 August 2025 - China-based Fosun Pharma (SSE:600196, HKEX: 02196) announced on Monday that its subsidiary Fosun Pharma Industrial has signed a licensing agreement with US-based Expedition Therapeuti...